**O17** THE BIOAVAILABILITY AND MATURING CLEARANCE OF DOXAPRAM IN PRETERM INFANTS

11FB Flint*, 1SHP Simons, 2P Andreissen, 1KD Liem, 1PLI Degraeveuw, 1IKM Reiks, 3R Ter Heine, 2AGI Engbers, 2BGP Koch, 3RF De Groot, 3DP Burgers, 12GAI Knibbe, 5SV Völker, DINO/Research Group, 1Department of Paediatrics, Division of Neonatology, Erasmus MC – Sophia Children’s Hospital; 2Department of Pharmacy, Erasmus MC, Rotterdam; 3Maxima Medical Centre, Veldhoven; 4Department of Neonatology, Radboud UMC-Amalia Children’s Hospital, Nijmegen; 5Department of Neonatology, Maastricht University Medical Centre, Maastricht; 6Department of Pharmacy and Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen; 7Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden; 8Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen; 9Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands

10.1136/archdischild-2019-esdppp.17

Background Doxapram is used for intravenous and oral treatment of apnea of prematurity in preterm infants. Dosing is currently based on bodyweight, however pharmacokinetic and bioavailability data are limited. To develop individualized dosing strategies, we characterized pharmacokinetics of doxapram in this vulnerable patient population.

Methods Data (302 samples) from 75 neonates were included with median (range) gestational age (GA) 25.9 (23.9–29.4) weeks, bodyweight 0.95 (0.48–1.61) kg, postnatal age (PNA) 17 (1–52) days at start of continuous treatment, and treatment duration of 16.8 (1.4–26.9) days. A population pharmacokinetic model was developed for doxapram and keto-doxapram.

Results A two-compartment model best described the pharmacokinetics of doxapram and its metabolite. PNA and GA affected the formation clearance of keto-doxapram (CLD-KD) and clearance of doxapram via other routes (CLD). For an individual of 0.95 kg, GA of 25.9 weeks and PNA of 17 days, CLD-KD was 0.096 L/h (residual standard error (RSE) 22%) and CLD 0.493 L/h (RSE 13%). Compared to PNA 30 days, estimated CLD-KD was 13% at PNA day 1 and 69% at day 15, and estimated CLD was 12% and 68%, respectively. Compared to GA 28 weeks, estimated CLD-KD was 63% at GA 24 weeks and 80% at 26 weeks, and estimated CLD was 67% and 81%, respectively. Oral bioavailability was estimated 74% (RSE 13%).

Conclusions With bodyweight-based dosing alone, preterm infants with the lowest PNA and GA had relatively low doxapram CL and the highest exposure. Therefore, the dose may be reduced by 50% up to PNA day 9, and by 25% for day 10–15. In addition, for GA dose may be reduced by 40% and 20% in newborns with GA of 24–25 weeks and 26–27 weeks, respectively, compared to 28–29 weeks. For switch to oral therapy a 33% dose increase is required to maintain plasma concentrations.

Disclosure(s) Nothing to disclose

**O18** THERAPEUTIC DELIVERY DURING BREASTFEEDING: A FEASIBILITY STUDY

1TM Maas*, 1POL Peirce, 1LB Baird, 2ST Whitehouse, 3NK Slater, 1K Beardsall. 1Department of Paediatrics; 2Department of Chemical Engineering and Biotechnology, University of Cambridge; 3Cambridge University Hospitals NHS Foundation Trust, Cambridge; 4College of Social Sciences, Arts and Humanities, University of Leicester, Leicester, UK

10.1136/archdischild-2019-esdppp.18

Background At an age when breastfeeding is the optimal nutritional support for infants, enteral drug delivery can be physically and emotionally challenging for parents. Delivery during breastfeeding could serve as an alternative to currently existing approaches. This study aimed to explore its feasibility and acceptability.

Methods Vitamin B12 was administered as part of a single-centre feasibility study to breastfed infants at the University of Cambridge Addenbrooke’s Hospital NHS Trust. Hereby a solid formulation (tablet) was placed inside an ultra-thin silicone nipple shield, and worn by a mother during the feed. The study investigated i) quantitative changes in B12 blood serum levels at baseline and 6–8 hours after the study feed, ii) mothers’ expectations and experiences via a mixed method approach by a single investigator. Local ethics approval was obtained prior to any study procedures being undertaken (18/L/0551).

Results Twenty dyads completed the study protocol. In all cases, no residual tablet was left after the feed, and the tablet’s presence within the shield did not appear to impact feeding. A pharmacokinetic-dependent vitamin B12 increase to 1871 pg/mL (610–4981 pg/mL) from a baseline of 533 pg/mL (236–925 pg/mL) was observed. Mothers described the nipple shield’s surprising ease of use and comfort for delivery, not affecting normal breastfeeding behaviour/sensation, while decreasing infant/maternal distress compared to the use of an oral syringe. All mothers expressed their wish for this approach to become available to parents in the future. Reasoning included the desire (1) of parents to have choices in relation to their infants’ health, (2) to replace a medical intervention with one that was felt to be more ‘natural’.

Conclusions This study showed that solid formulations can be used for therapeutic delivery whilst breastfeeding and is viewed by mothers as advantageous compared to currently available methods.

Disclosure(s) Funding The research was supported by a WD Armstrong PhD studentship for the Application of Engineering in Medicine, University of Cambridge, the German Academic Scholarship Foundation, and the Kurt Hahn Trust, University of Cambridge. Competing interests (applicable to all authors): None declared.

**O19** DEVELOPMENT OF A PAEDIATRIC BRAIN PBPK MODEL IN CHILDREN WITH AND WITHOUT MENINGITIS

1LFM Verscheijden*, 1JB Koenderink, 1K Allegaert, 1SN de Wildt, 1FGM Russel. 1Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Nijmegen; 2Intensive Care and Department of Paediatric Surgery, Erasmus MC – Sophia Childrens Hospital, Rotterdam, The Netherlands; 3Department of Development and Regeneration, KU Leuven, Leuven, Belgium

10.1136/archdischild-2019-esdppp.19

Background Several paediatric physiologically-based pharmacokinetic (PBPK) models have been developed that incorporate developmental changes affecting plasma drug concentrations. Disposition into cerebrospinal fluid (CSF) is also age-related and influenced by physiological factors, including CSF production rate, but also by brain diseases, such as meningitis, which are associated with impaired blood-brain barrier integrity. Our aim was to develop a paediatric brain PBPK model to predict CSF drug concentrations in children with and without meningitis.

Methods A paediatric PBPK model was developed incorporating age-appropriate parameters and associated inter-individual
variability. The model was validated for paracetamol, ibuprofen, flurbiprofen and naproxen, and for a paediatric meningitis population by estimating meropenem blood-brain barrier penetration using sensitivity analysis. Plasma and CSF drug concentrations derived from literature were used to perform visual predictive checks and to calculate ratios between simulated and observed AUCs in order to evaluate model performance.

**Results** Simulated data were comparable to observed over a broad age range (1 day - 15 y postnatal age), for all drugs investigated. The ratios between observed and simulated AUCs were within 2-fold difference both in plasma and in CSF, indicating acceptable model performance. Disposition of meropenem into the brain was slow and CSF concentrations were lower compared to plasma concentrations. In addition, several days were needed to achieve CSF steady-state concentration.

**Conclusions** Our paediatric brain PBPK model provides a new tool to predict CSF concentrations in children with and without meningitis and can be used as a template model for other drugs acting in the CNS.

**Disclosure(s)** Nothing to disclose.

---

**PROGRESS TOWARDS THERAPEUTIC DRUG MONITORING VIA BREATHE ANALYSIS**

**Background** Therapeutic Drug Monitoring (TDM) is essential for the clinical management of patients. However, despite the clear advantages of TDM, it faces several challenges to being more widely used in the clinic. Specialty challenging is the case of TDM in children, as they experience rapid physiologic developments, leading to great pharmacokinetic and pharmacodynamic variability. Breath analysis provides a patient-friendly approach to support TDM. To explore this possibility, we are currently running a pilot study, whereby we analyze the exhaled breath of pediatric patients receiving anti-seizure or chemotherapy drugs requiring TDM.

**Methods** We analyzed by secondary electrospray ionization-high resolution mass spectrometry (ESI-HRMS) exhaled breath of pediatric patients under therapy for Valproic acid (VPA; n = 27), Lamotrigine (n = 19), Levetiracetam (n = 15), Oxcarbazepine (n = 11) and Methotrexate (n = 4). Systemic blood concentrations were measured simultaneously to the breath test. In the case of VPA, we constructed a regression model to predict systemic blood concentrations based on the signal intensity of breath mass spectral features. For the rest of the drugs listed, due to its current limited size, we conducted preliminary data visualization approaches.

**Results** We found that exhaled metabolites of VPA allow to predict free VPA blood concentrations with a root-mean-square error of 1.5 mg/L for concentrations in the range 0–12 mg/L. This prediction is accomplished within 20 minutes, comprising the breath test and data analysis. For Levetiracetam, Lamotrigine and Oxcarbazepine the data analysis is still ongoing. For MTX we found breath metabolites clearly altered as a result of the drug administration. However, a great inter-individual variability was also observed.

**Conclusion** We conclude that breath analysis may support current TDM approaches. This will lead to new opportunities to guide the dose of drugs with a high level of accuracy, in real-time and non-invasively.

**Disclosure(s)** PS gratefully acknowledges the financial support of the Fondation Botnar (Switzerland) and the Swiss National Science Foundation (320030_173168 and PCEGP3_181300). PS is part of the board of directors of Deep Breath Initiative AG. JU was supported by research fellowship of the University Children’s Hospital Basel. VS and JVDA were supported by the Eckenstein-Geigy Foundation. *AD and PS: shared senior authorship.